Option B+ for prevention of mother-to-child transmission of HIV in resource-constrained settings: great promise but some early caution.
aWorld Health Organization, Department of HIV/AIDS, Geneva, Switzerland bICAP, Mailman School of Public Health and College of Physicians and Surgeons, Columbia University, New York, New York, USA cINSERM, Centre INSERM U897 'Epidémiologie et Biostatistique' dUniversité Bordeaux Segalen, Institut de Santé Publique Epidémiologie Développement (ISPED), Bordeaux, France.
Nathan
N
Shaffer
Elaine J
EJ
Abrams
Renaud
R
Becquet
D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D001942:Breast Feeding; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D059012:Lost to Follow-Up; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*
D044966:Anti-Retroviral Agents